Japan approved its 39-trillion-yen economic stimulus package on November 22. It does not explicitly state that the drug price revision…
HOME > ACADEMIA
ACADEMIA
- Evrysdi Debut Expands SMA Treatment Options, Improved Use Expected for All 3 Drugs: Professor
August 16, 2021
- Osteoporosis Society Greatly Alarmed by Vitamin D3 Analog Shortages, Might Take Further Measures
July 29, 2021
- Scientific Societies Propose Measures for Osteoporosis Treatment amid Shortages of Vitamin D Analogs
July 21, 2021
- Japan KOL Pins Hopes on Pemazyre as 1st Biliary Tract Cancer Drug in 9 Years
July 16, 2021
- Japan Needs Discussions on Target Population of Aducanumab: Clinician
July 12, 2021
- Pregnant Women Can Get COVID-19 Vaccinations: Japan OB/GYN Societies
June 29, 2021
- Architect of Oncolytic Virus Therapy Looks to Its Use in All Solid Cancers in 5 Years
June 25, 2021
- Reproductive Medicine Society Issues Fertility Treatment Guidelines, Prods Careful Design for Health Coverage
June 25, 2021
- As Aducanumab Decision Nears, Health Economist Stresses Need for Broad Value Evaluation, Target Patient Criteria
June 4, 2021
- NCC, 5 Other Institutions Forge Genome Cohort of 366,000 People
May 28, 2021
- Hematologist Sees No Swelling Costs from 2 New CAR-T Contenders in Japan; Will Competition Drive Down Prices?
May 28, 2021
- New AMR Prevention Technology Could Contribute to Antiviral Development; Application to COVID-19 Meds Expected: Professor
May 17, 2021
- Olumiant Expected to Shorten Time to Recovery from COVID-19: Infection Expert
May 12, 2021
- No. of New Lung Cancer Patients Fell 6.6% in 2020 amid COVID-19: Survey
May 11, 2021
- Survival Rate Declines for Some Cancers Even after 5 Years: NCC
April 28, 2021
- New RA Guidelines Upgrade Position of JAK Inhibitors, Biosimilars on Equal Footing with Reference Products
April 26, 2021
- Tokushukai Weighs Switches from Nichi-Iko Products after Biz Suspension Order
March 15, 2021
- COVID-19 Vaccination Should Be Avoided in Patients with Severe Hypersensitivity to PEG: Allergy Society
March 3, 2021
- Thorough Medication Guidance through Regional Collaboration Important for Rybelsus: Professor
February 22, 2021
- NCGM to Initiate Clinical Study of Convalescent Plasma Therapy for COVID-19 as Early as February
January 28, 2021
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…